BioLight   Report issue

For profit Phase 2
Founded: Tel Aviv Israel (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2014
NCT02129673
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

latanoprost (xalatan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glaucoma (Phase 2)

Glaucoma, Open-Angle (Phase 2)

Hypertension (Phase 2)

Ocular Hypertension (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1